<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4023363/" ref="ordinalpos=1094&amp;ncbi_uid=6160892&amp;link_uid=PMC4023363" image-link="/pmc/articles/PMC4023363/figure/F1/" class="imagepopup">Figure 1.  From: PI3K-AKT-mTOR <span class="highlight" style="background-color:">signaling</span> in prostate cancer progression and androgen deprivation therapy resistance. </a></div><br /><div class="p4l_captionBody">The PI3K-AKT-mTOR signaling pathway and therapeutic opportunities. (<b>a</b>) A simplified schematic of PI3K-AKT-mTOR signaling and therapeutic targets. (<b>b-d</b>) The molecular interplay between the PI3K and AR signaling axes. ARE: androgen response element; mTOR: mammalian target of rapamycin; PI3K: phosphoinositide 3-kinase; AR: androgen receptor; RTK: receptor tyrosine kinase; GPCR: G-protein coupled receptor.</div></div>